Bausch Health Sues Alvogen to Block Copies of Xifaxan IBS Drug

Bausch Health said Alvogen’s proposed generic version of a treatment for irritable bowel syndrome with diarrhea infringes 23 patents for Xifaxan 550 milligram tablets.

• Bausch is seeking a court order blocking copies until the patents have expired, according to complaint filed Thursday in federal court in Wilmington, Delaware
• Patents expire in June 2024; February and June 2025; February 2026; September 2027; February, July and October 2029; and March 2030, according to supplemental filing
• Closely held Alfasigma owns 13 of the patents and exclusively licenses them to Bausch, complaint says
• Xifaxan had sales of $1.45 billion in 2019, 16.9% of ...